TICKERNERD
Menu
TECHTECHHealthcare · Biotechnology

TECH Stock Forecast: Bio-Techne Corp. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$72
+0.21% on the day

The 14 Wall Street analysts covering Bio-Techne Corp. hold a median 12-month price target of $73 — +0.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$11.3B
Ticker Nerd rank
94 / 100
Median analyst target
$73
Analysts covering
14
Revenue$311.4M−1.5% y/y
Operating income$75.5M
Net income$51.0M
Free cash flow$77.6M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.1%
1M
+1.2%
YTD
+23.6%
1Y
+27.5%
From 52W high
−0.0%
From 52W low
+67.6%
$43
$72
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TECH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bio-Techne Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
89
Momentum
87
Volatility
86
Value
82
Quality
77
Accruals
73
Growth
66
Revisions
66
Size
15

Issuance (89): The share count has been shrinking and the company is not leaning on new borrowing.

Revisions (66): Analysts have, on balance, been cutting their forecasts.

Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TECH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TECH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$50$60$70$80Oct 25Jan 26Apr 26Jul 26TECHHigh $73Median $73Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
1 Buy13 Hold0 Sell
Low $50Median $73High $73

The green dot is the last close — the median target sits +0.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2026Wells FargoDowngradeEqual-Weight$62 → $73
9 July 2026RBC CapitalDowngradeSector Perform—
9 July 2026RBC CapitalDowngradeSector Perform$62 → $73
30 June 2026BenchmarkDowngradeHold—
30 June 2026TD CowenDowngradeHold—
29 June 2026CitigroupDowngradeNeutral—
26 June 2026BairdMaintainsNeutral—
26 June 2026Stephens & Co.DowngradeEqual-Weight—
26 June 2026William BlairDowngradeMarket Perform—
11 June 2026Piper SandlerInitiatesNeutral—
15 May 2026RBC CapitalReinstatesOutperform$62
7 May 2026CitigroupMaintainsBuy—
7 May 2026Evercore ISI GroupMaintainsIn-Line—
7 May 2026Wells FargoMaintainsOverweight—
6 Apr 2026Evercore ISI GroupMaintainsIn-Line—
6 Feb 2026Wells FargoMaintainsOverweight—
5 Feb 2026CitigroupMaintainsBuy—
5 Feb 2026Evercore ISI GroupMaintainsIn-Line—
5 Feb 2026StifelMaintainsHold—
5 Feb 2026TD CowenMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TECH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TECH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Bio-Techne Corp. returned +27.5% against +19.6% for the S&P 500, dividends included.

TECH vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130Oct 25Jan 26Apr 26Jul 26TECHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TECH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Bio-Techne Corp. (TECH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
62.3×

Cheaper than 12% of US stocks

Price / sales
9.3×

Cheaper than 16% of US stocks

Price / book
5.4×

Cheaper than 20% of US stocks

EV / EBITDA
31.8×

Cheaper than 8% of US stocks

Growth & margins
Revenue growth (YoY)
1.3%

Higher than 30% of US stocks

Earnings growth (YoY)
−1.5%

Higher than 34% of US stocks

Gross margin
66.9%

Higher than 80% of US stocks

Operating margin
23.5%

Higher than 82% of US stocks

Net margin
15.0%

Higher than 77% of US stocks

Returns & dividend
Return on equity
9.0%

Higher than 61% of US stocks

Return on assets
6.3%

Higher than 82% of US stocks

Dividend yield
0.4%

Higher than 9% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bio-Techne Corp. (TECH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bio-Techne Corp. has a market value of $11.3B and an enterprise value of $11.3B.

  • Revenue in the twelve months to 31 Mar 2026: $1.2B. The latest quarter grew 1.3% year on year.

  • Net income over the same four quarters: $109.6M, a 9.0% net margin.

  • Diluted earnings per share, trailing twelve months: $0.69.

  • Free cash flow in the twelve months to 31 Mar 2026: $269.6M, after $25.3M of capital spending.

  • Bio-Techne Corp. spent $100.1M on share buybacks and $49.8M on dividends in the twelve months to 31 Mar 2026.

  • Shares outstanding: 156.5M.

  • Trailing P/E: 62.3×; forward P/E: 31.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.44%, paying out 28% of earnings.

  • Bio-Techne Corp. employs 3,000 people — $404K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

TECH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TECHBio-Techne Corp.$11.3B
94
MDGLMadrigal Pharmaceuticals, Inc.$11.9B
69
AXSMAxsome Therapeutics, Inc.$10.7B
74
CYTKCytokinetics, Inc.$10.7B
53
SMMTSummit Therapeutics, Inc.$10.5B
19
ARWRArrowhead Pharmaceuticals, Inc.$12.2B
59
HALOHalozyme Therapeutics, Inc.$12.3B
97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bio-Techne Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TECH news & analysis

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)

GlobeNewsWire · 24 Aug 2026neutral

Brodsky & Smith, a law firm, is notifying investors of investigations it is conducting into several companies, including Bio-Techne Corporation. The firm invites shareholders who wish to discuss the investigations to contact it at no cost.

Why it matters — A law firm investigation involving Bio-Techne could signal potential shareholder concerns, and a Bio-Techne watcher would want to monitor for any related developments.

TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders

Business Wire · 22 Aug 2026negative

Investor rights law firm Halper Sadeh LLC announced it is investigating the sale of Bio-Techne Corporation to Merck KGaA for $73.00 per share in cash, examining whether Bio-Techne and its board of directors obtained a fair price for shareholders. The firm is encouraging shareholders to learn about their rights and options in connection with the transaction.

Why it matters — A TECH watcher would care because the investigation raises questions about the fairness of the $73.00 cash-per-share acquisition price and the board's conduct in the deal.

TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises

Zacks Investment Research · 13 Aug 2026positive

Bio-Techne reported Q4 earnings that met estimates and revenues that surpassed expectations, driven by strong organic growth in Diagnostics and Spatial Biology. The company's stock rose following the results, with its Merck deal also in focus.

Why it matters — TECH watchers would care because the revenue beat and share price increase signal continued momentum in key growth areas like Diagnostics and Spatial Biology, while the Merck partnership remains a notable catalyst.

Bio-Techne Corrects Dividend Announcement

PRNewsWire · 13 Aug 2026neutral

Bio-Techne Corporation issued a correction to its dividend announcement from the previous day. The initial version incorrectly listed the shareholder of record date as August 17, 2026, and the company has now corrected this information.

Why it matters — A TECH watcher would care because the corrected dividend record date affects the timeline for shareholders to be eligible to receive the upcoming dividend payment.

Techne (TECH) Q4 Earnings Meet Estimates

Zacks Investment Research · 12 Aug 2026neutral

Bio-Techne (TECH) reported fourth-quarter earnings of $0.52 per share, matching the Zacks Consensus Estimate and down slightly from $0.53 per share in the same quarter a year earlier.

Why it matters — The result confirms Bio-Techne met analyst expectations for the quarter, giving investors a benchmark on its recent earnings trajectory.

FAQ

Frequently asked questions about TECH stock

What is the TECH stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Bio-Techne Corp. have a median 12-month price target of $73, with estimates ranging from $50 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TECH stock a buy right now?

Of the 14 analysts covering Bio-Techne Corp., 1 rate it a Buy, 13 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bio-Techne Corp. 94 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TECH?

As at 22 Aug 2026, Bio-Techne Corp. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (89 of 100).

Will TECH stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +0.8% from the last close, and Ticker Nerd's factor model ranks Bio-Techne Corp. 94 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TECH stock forecast for 2030?

No analyst covering Bio-Techne Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TECH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $73 over the next 12 months.

How has TECH stock performed over the past year?

Bio-Techne Corp. returned +27.5% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bio-Techne Corp. do?

Bio-Techne Corporation is a global life sciences company that develops, manufactures, and supplies specialized tools for research and clinical diagnostics. The company focuses on high-quality reagents, analytical instruments, and precision diagnostic products used across pharmaceutical, biotechnology, academic, and clinical laboratory settings.

What is the latest news on TECH?

The most recent item we track (GlobeNewsWire, 24 Aug 2026): "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)". Brodsky & Smith, a law firm, is notifying investors of investigations it is conducting into several companies, including Bio-Techne Corporation. The firm invites shareholders who wish to discuss the investigations to contact it at no cost.

Company

About Bio-Techne Corp.

Bio-Techne Corporation is a global life sciences company that develops, manufactures, and supplies specialized tools for research and clinical diagnostics. The company focuses on high-quality reagents, analytical instruments, and precision diagnostic products used across pharmaceutical, biotechnology, academic, and clinical laboratory settings. Through its protein sciences activities, Bio-Techne provides antibodies, bioactive proteins, assays, and related instruments that support investigations into cellular pathways, disease mechanisms, and therapeutic targets. Its diagnostics and spatial biology offerings include diagnostic reagents, molecular diagnostic solutions, and advanced platforms for visualizing and quantifying biomolecules in tissues, supporting pathology and translational research. Bio-Techne serves a diversified customer base involved in drug discovery, basic and applied research, and high-complexity diagnostic testing, helping ensure reproducible and consistent experimental results. Incorporated in 1981 and headquartered in Minneapolis, Minnesota, Bio-Techne today plays a significant role in the global life sciences infrastructure by providing critical consumables and instruments that are embedded in laboratory workflows worldwide.

CEO Mr. Kim Kelderman · 3,000 employees · United States · https://www.bio-techne.com